

UNITED STATES PATENT AND TRADEMARK OFFICE

(12) CERTIFICATE EXTENDING PATENT TERM
UNDER 35 U.S.C. § 156

(68) PATENT NO. : 5,750,497
(45) ISSUED : May 12, 1998
(75) INVENTOR : Svend Havelund et al.
(73) PATENT OWNER : Novo Nordisk A/S
(95) PRODUCT : LEVEMIR® [insulin detemir (rDNA origin)
injection]


This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 5,750,497 based upon the regulatory review of the product LEVEMIR® [insulin detemir (rDNA origin) injection] by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

(94) 1,497 days

from May 12, 2015, the original expiration date of the patent, subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the United States Patent and Trademark Office to be affixed this 17th day of January 2008.



JON W. DUDAS
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office